Biora Therapeutics, Inc. BIOR
Set alert
0.22 USD 0.00 0.00%
As of Mar 13, 9:30 AM ET
0.22 Day range 0.22
0.26 52-week range 19.90
- YTD
- 0.00%
- 1 year
- 0.00%
- Open
- 0.22
- Prev close
- 0.22
- Mkt cap
- 2.04M
- Vol
- 169.45K
- Avg vol
- 132.00K
- EPS
- 0.36
- P/E
- 1.25
- Div yield
- 0.00%
More statistics
- Low
- 0.22
- High
- 0.22
- Forward P/E
- -0.04
- Beta
- 0.00
- Short ratio
- 2.37
- Inst. own
- 36.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 12, 2024
- 50-d avg
- 2.44
- 200-d avg
- 5.90
- 1y target
- 34.00
2Y chart
Events in this range
- Mar 26, 2024Earnings: —; estimate -6; surprise —%
- May 15, 2024Earnings: -6.1; estimate -4.5; surprise -35.56%
- May 15, 2024Earnings: —; estimate -4.5; surprise —%
- May 16, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Jul 22, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Aug 12, 2024Earnings: —; estimate -4.5; surprise —%
- Aug 12, 2024Earnings: -3.5; estimate -4.5; surprise 22.22%
- Aug 13, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Oct 18, 2024Split: 1 for 10
- Nov 14, 2024Earnings: -6.08; estimate -3.85; surprise -57.92%
- Nov 18, 2024Rating: HC Wainwright & Co. · Buy → Buy
Signals (43)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Dec 18, 2024 | 1 year ago |
| MACD: Sell Signal | Dec 11, 2024 | 1 year ago |
| RSI: Oversold | Dec 3, 2024 | 1 year ago |
| MACD: Buy Signal | Nov 26, 2024 | 1 year ago |
| RSI: Oversold | Nov 13, 2024 | 1 year ago |
| RSI: Oversold | Nov 4, 2024 | 1 year ago |
| RSI: Oversold | Oct 23, 2024 | 2 years ago |
| MACD: Sell Signal | Oct 18, 2024 | 2 years ago |
| MACD: Buy Signal | Oct 8, 2024 | 2 years ago |
| RSI: Oversold | Sep 26, 2024 | 2 years ago |
| RSI: Oversold | Sep 23, 2024 | 2 years ago |
| SMA: Bearish | Sep 13, 2024 | 2 years ago |
| SMA: Bullish | Sep 12, 2024 | 2 years ago |
| MACD: Sell Signal | Sep 5, 2024 | 2 years ago |
| SMA: Bearish | Sep 4, 2024 | 2 years ago |
| SMA: Bullish | Aug 23, 2024 | 2 years ago |
| SMA: Bearish | Aug 22, 2024 | 2 years ago |
| SMA: Bullish | Aug 19, 2024 | 2 years ago |
| SMA: Bearish | Aug 14, 2024 | 2 years ago |
| MACD: Buy Signal | Aug 14, 2024 | 2 years ago |
| SMA: Bullish | Aug 13, 2024 | 2 years ago |
| SMA: Bearish | Jul 31, 2024 | 2 years ago |
| MACD: Sell Signal | Jul 25, 2024 | 2 years ago |
| SMA: Bearish | Jul 24, 2024 | 2 years ago |
| SMA: Bullish | Jul 22, 2024 | 2 years ago |
| SMA: Bearish | Jul 19, 2024 | 2 years ago |
| SMA: Bullish | Jul 15, 2024 | 2 years ago |
| MACD: Buy Signal | Jul 11, 2024 | 2 years ago |
| SMA: Bearish | Jun 26, 2024 | 2 years ago |
| MACD: Sell Signal | Jun 25, 2024 | 2 years ago |
| SMA: Bullish | Jun 18, 2024 | 2 years ago |
| SMA: Bearish | Jun 17, 2024 | 2 years ago |
| SMA: Bullish | Jun 6, 2024 | 2 years ago |
| MACD: Buy Signal | Jun 4, 2024 | 2 years ago |
| MACD: Sell Signal | May 23, 2024 | 2 years ago |
| RSI: Oversold | May 23, 2024 | 2 years ago |
| MACD: Buy Signal | Apr 25, 2024 | 2 years ago |
| RSI: Oversold | Apr 18, 2024 | 2 years ago |
| RSI: Oversold | Apr 15, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 27, 2024 | 2 years ago |
| MACD: Buy Signal | Mar 26, 2024 | 2 years ago |
| MACD: Sell Signal | Mar 14, 2024 | 2 years ago |
| RSI: Overbought | Feb 27, 2024 | 2 years ago |
Key statistics
- Market cap
- 2.04M
- Enterprise value
- 0
- Trailing P/E
- 1.25
- Forward P/E
- -0.04
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.36
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 0.00%
- Shares outstanding
- 4.52M
- Short % of float
- 8.58%
- 50-day average
- 2.44
- 200-day average
- 5.90
Analyst view
Consensus: none
Price target (mean) 34.00 +15354.5% upside
Now 0.22
- Target (low)
- 23.00
- Target (mean)
- 34.00
- Target (high)
- 45.00
Ratings (0m) 1 1 buy · 0 hold · 0 sell
- Strong buy1
- Buy0
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate 0.00.
Financials — quick view
BIOR Revenue — quarterly 32.00K
BIOR Net income — quarterly -18.40M
BIOR EPS — quarterly -5.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -3.85 | -6.08 | -2.23 | -57.92% |
| Aug 12, 2024 | Jun 1, 2024 | -4.50 | — | — | — |
| Aug 12, 2024 | Jun 1, 2024 | -4.50 | -3.50 | +1.00 | +22.22% |
| May 15, 2024 | Mar 1, 2024 | -4.50 | -6.10 | -1.60 | -35.56% |
| May 15, 2024 | Mar 1, 2024 | -4.50 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -6.00 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 18, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 22, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jan 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 2, 2023 | HC Wainwright & Co. | main | Buy | Buy |
About Biora Therapeutics, Inc.
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bioratherapeutics.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on BIOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALTER JEFFREY D | Director | Stock Award(Grant) | Jun 4, 2024 | 31,546 |
| ATHYRIUM OPPORTUNITIES III CO-INVEST 1 L.P. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Sep 17, 2023 | 0 |
| D'ESPARBES ERIC | Chief Financial Officer | Stock Award(Grant) | Feb 14, 2024 | 603,662 |
| HOWE JILL ANN | Director | Stock Award(Grant) | Jun 4, 2024 | 31,916 |
| KOTZIN BRIAN L | Director | Stock Award(Grant) | Jun 4, 2024 | 30,746 |
| MOHANTY ADITYA P | Chief Executive Officer | Stock Award(Grant) | Feb 14, 2024 | 1,539,490 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Athyrium Capital Management, LP | 24.17% | 1,092,976 | 491.84K | Sep 29, 2024 |
| Vanguard Group Inc | 1.54% | 69,733 | 31.38K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.35% | 15,630 | 7.03K | Sep 29, 2024 |
| Morgan Stanley | 0.32% | 14,503 | 6.53K | Sep 29, 2024 |
| Northern Trust Corporation | 0.15% | 6,857 | 3.08K | Sep 29, 2024 |
| Blackrock Inc. | 0.14% | 6,161 | 2.77K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.82% | 37,203 | 16.74K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.72% | 32,530 | 14.64K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.18% | 8,291 | 3.73K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.08% | 3,487 | 1.57K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.04% | 1,724 | 775 | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.03% | 1,408 | 633 | Oct 30, 2024 |